Tumor stroma as a target in cancer

Area of Science:

• Oncology
• Cancer Biology
• Immunotherapy

Background:

• Solid tumors comprise malignant cells and a complex stroma, including fibroblasts, vasculature, and immune cells like macrophages.
• Traditional cancer therapies focused on malignant cells, yielding limited success, prompting exploration of novel strategies.
• Anti-angiogenesis and vascular targeting have emerged as promising avenues, shifting focus towards the tumor microenvironment.

Purpose of the Study:

• To highlight the tumor stroma as a novel anti-cancer target.
• To review recent advancements in targeting tumor vasculature, fibroblasts, and macrophages.
• To discuss the potential for developing cancer vaccines based on tumor endothelium.

Main Methods:

• Review of current literature on anti-angiogenics and vascular disrupting agents.
• Analysis of studies investigating stromal fibroblasts and tumor-associated macrophages.
• Exploration of tumor endothelial markers for target identification.
• Discussion of immunotherapy and cancer vaccine development.

Main Results:

• Anti-angiogenic therapies are entering clinical practice.
• Vascular disrupting agents, stromal fibroblasts, and macrophages are actively being researched as therapeutic targets.
• Tumor endothelial markers are being identified for targeted therapies.
• The genetic stability of tumor endothelium presents a viable target for cancer vaccines, enhanced by immunotherapy.

Conclusions:

• The tumor stroma represents a promising frontier for developing innovative cancer therapies.
• Targeting tumor vasculature and immune components offers new hope for treatment.
• Cancer vaccines targeting tumor endothelium are becoming a realistic possibility due to advances in immunotherapy.